FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1537583887> ?p ?o ?g. }

• W1537583887 endingPage "734" @default.
• W1537583887 startingPage "723" @default.
• W1537583887 abstract "A long-standing goal in genetic therapy for cancer is a systemic gene delivery system that selectively targets tumor cells, including metastases. Here we describe a novel cationic immunolipoplex system that shows high in vivo gene transfer efficiency and antitumor efficacy when used for systemic p53 gene therapy of cancer. A cationic immunolipoplex incorporating a biosynthetically lipid-tagged, anti-transferrin receptor single-chain antibody (TfRscFv), was designed to target tumor cells both in vitro and in vivo. A human breast cancer metastasis model was employed to evaluate the in vivo efficacy of systemically administered, TfRscFv-immunolipoplex-mediated, p53 gene therapy in combination with docetaxel. The TfRscFv-targeting cationic immunolipoplex had a size of 60–100 nm, showed enhanced tumor cell binding, and improved targeted gene delivery and transfection efficiencies, both in vitro and in vivo. The p53 tumor suppressor gene was not only systemically delivered by the immunolipoplex to human tumor xenografts in nude mice but also functionally expressed. In the nude mouse breast cancer metastasis model, the combination of the p53 gene delivered by the systemic administration of the TfRscFv-immunolipoplex and docetaxel resulted in significantly improved efficacy with prolonged survival. This is the first report using scFv-targeting immunolipoplexes for systemic gene therapy. The TfRscFv has a number of advantages over the transferrin (Tf) molecule itself: (1) scFv has a much smaller size than Tf producing a smaller immunolipoplex giving better penetration into solid tumors; (2) unlike Tf, the scFv is a recombinant protein, not a blood product; (3) large scale production and strict quality control of the recombinant scFv, as well as scFv-immunolipoplex, are feasible. The sensitization of tumors to chemotherapy by this tumor-targeted and efficient p53 gene delivery method could lower the effective dose of the drug, correspondingly lessening the severe side effects, while decreasing the possibility of recurrence. Moreover, this approach is applicable to both primary and recurrent tumors, and more significantly, metastatic disease. The TfRscFv-targeting of cationic immunolipoplexes is a promising method of tumor targeted gene delivery that can be used for systemic gene therapy of cancer with the potential to critically impact the clinical management of cancer." @default.
• W1537583887 created "2016-06-24" @default.
• W1537583887 creator A5016173849 @default.
• W1537583887 creator A5036796437 @default.
• W1537583887 creator A5039264253 @default.
• W1537583887 creator A5047405531 @default.
• W1537583887 creator A5048276478 @default.
• W1537583887 creator A5052044401 @default.
• W1537583887 creator A5053441593 @default.
• W1537583887 creator A5055186161 @default.
• W1537583887 date "2001-10-01" @default.
• W1537583887 modified "2023-10-16" @default.
• W1537583887 title "Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv" @default.
• W1537583887 cites W11138111 @default.
• W1537583887 cites W1506576730 @default.
• W1537583887 cites W151192786 @default.
• W1537583887 cites W1707491378 @default.
• W1537583887 cites W1760955494 @default.
• W1537583887 cites W1933883184 @default.
• W1537583887 cites W1944263241 @default.
• W1537583887 cites W1966305351 @default.
• W1537583887 cites W1972678416 @default.
• W1537583887 cites W1976570855 @default.
• W1537583887 cites W1990111799 @default.
• W1537583887 cites W1990401132 @default.
• W1537583887 cites W2000457660 @default.
• W1537583887 cites W2007473681 @default.
• W1537583887 cites W2026841999 @default.
• W1537583887 cites W2027344275 @default.
• W1537583887 cites W2031472030 @default.
• W1537583887 cites W2033799417 @default.
• W1537583887 cites W2034107535 @default.
• W1537583887 cites W2040244557 @default.
• W1537583887 cites W2040306475 @default.
• W1537583887 cites W2047621818 @default.
• W1537583887 cites W2061165346 @default.
• W1537583887 cites W2066986283 @default.
• W1537583887 cites W2069060151 @default.
• W1537583887 cites W2081578114 @default.
• W1537583887 cites W2090728231 @default.
• W1537583887 cites W2100751439 @default.
• W1537583887 cites W2103036523 @default.
• W1537583887 cites W2103924161 @default.
• W1537583887 cites W2137155864 @default.
• W1537583887 cites W2158254083 @default.
• W1537583887 cites W2164380696 @default.
• W1537583887 cites W2254253530 @default.
• W1537583887 cites W2319449285 @default.
• W1537583887 cites W2329652372 @default.
• W1537583887 cites W2355272857 @default.
• W1537583887 cites W4211033169 @default.
• W1537583887 cites W4240135270 @default.
• W1537583887 doi "https://doi.org/10.1007/bf03401962" @default.
• W1537583887 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1949994" @default.
• W1537583887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11713371" @default.
• W1537583887 hasPublicationYear "2001" @default.
• W1537583887 type Work @default.
• W1537583887 sameAs 1537583887 @default.
• W1537583887 citedByCount "137" @default.
• W1537583887 countsByYear W15375838872012 @default.
• W1537583887 countsByYear W15375838872013 @default.
• W1537583887 countsByYear W15375838872014 @default.
• W1537583887 countsByYear W15375838872015 @default.
• W1537583887 countsByYear W15375838872016 @default.
• W1537583887 countsByYear W15375838872017 @default.
• W1537583887 countsByYear W15375838872018 @default.
• W1537583887 countsByYear W15375838872019 @default.
• W1537583887 countsByYear W15375838872020 @default.
• W1537583887 countsByYear W15375838872021 @default.
• W1537583887 countsByYear W15375838872022 @default.
• W1537583887 countsByYear W15375838872023 @default.
• W1537583887 crossrefType "journal-article" @default.
• W1537583887 hasAuthorship W1537583887A5016173849 @default.
• W1537583887 hasAuthorship W1537583887A5036796437 @default.
• W1537583887 hasAuthorship W1537583887A5039264253 @default.
• W1537583887 hasAuthorship W1537583887A5047405531 @default.
• W1537583887 hasAuthorship W1537583887A5048276478 @default.
• W1537583887 hasAuthorship W1537583887A5052044401 @default.
• W1537583887 hasAuthorship W1537583887A5053441593 @default.
• W1537583887 hasAuthorship W1537583887A5055186161 @default.
• W1537583887 hasBestOaLocation W15375838871 @default.
• W1537583887 hasConcept C104317684 @default.
• W1537583887 hasConcept C111599444 @default.
• W1537583887 hasConcept C121608353 @default.
• W1537583887 hasConcept C126322002 @default.
• W1537583887 hasConcept C135983454 @default.
• W1537583887 hasConcept C150903083 @default.
• W1537583887 hasConcept C203014093 @default.
• W1537583887 hasConcept C207001950 @default.
• W1537583887 hasConcept C22814914 @default.
• W1537583887 hasConcept C25938499 @default.
• W1537583887 hasConcept C2779013556 @default.
• W1537583887 hasConcept C2781190966 @default.
• W1537583887 hasConcept C32264632 @default.
• W1537583887 hasConcept C502942594 @default.
• W1537583887 hasConcept C55493867 @default.
• W1537583887 hasConcept C71924100 @default.
• W1537583887 hasConcept C86803240 @default.

• next